Prostate cancer. Primary hormonal treatment

Area of Science:

• Oncology
• Endocrinology
• Prostate Cancer Research

Background:

• Primary hormonal therapy is the established first-line treatment for symptomatic metastatic prostate cancer.
• It demonstrates high objective (40-60%) and subjective (up to 80%) response rates.
• No other treatment currently surpasses these response rates.

Purpose of the Study:

• To review treatment outcomes in metastatic prostate cancer.
• To evaluate the efficacy of different endocrine treatments.
• To highlight the importance of personalized treatment approaches.

Main Methods:

• Review of existing endocrine treatments for metastatic prostate cancer.
• Analysis of prognostic factors influencing treatment outcomes.
• Comparison of response rates across different therapeutic strategies.

Main Results:

• Maximal androgen blockade shows the greatest response and modest survival increase.
• Hormonal therapy remains the gold standard for first-line treatment.
• Nonsteroidal antiandrogen monotherapy can preserve potency in select patients.

Conclusions:

• Treatment outcomes depend on initial and intermittent prognostic factors.
• A tailored, pilot treatment approach adjusted to patient needs and preferences is recommended.
• Personalized medicine is crucial for optimizing metastatic prostate cancer management.